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Abstract: Objective: B-cell expansion is a key feature of Sjögren’s syndrome (SS). Accordingly, several studies have re-
ported the benefits of B-cell depletion with anti-CD20 monoclonal antibody (Rituximab) in the treatment of glandular and 
extraglandular manifestations of SS. Patients with SS are at increased risk of lymphoma development. B-lymphocyte 
stimulator (BAFF) is an essential cytokine for the control of B-cell maturation and survival, and high levels of BAFF were 
described in the serum and salivary glands of SS patients, strongly suggesting a crucial role in the proliferation of B cells 
in SS.  
Patient and Methods: we describe the treatments employed, with particular regards to rituximab therapy, and the histopa-
thologic and biologic studies, in particular BAFF levels in serum and in pathologic tissues before and after B-cell deple-
tion therapy, and the characterization of the cultured epithelial cells obtained by the parotid gland MALT-lymphoma, in a 
case of a 51-year old woman with primary SS and mixed cryoglobulinaemia type II with features of systemic vasculitis, 
who developed a bilateral parotid MALT-type lymphoma. Rheumatoid factor (RF), cryoglobulins, BAFF levels were as-
sessed monthly up to month +6, then at the end of follow-up (month +12), as well as peripheral blood CD19-positive B-
cell level.  
Results: a significant systemic effect of rituximab on B-cell biomarkers was documented, however, the cryoglobulinemic 
syndrome did not improve and the parotid enlargement did not decrease confirming the failure of B-cell depletion to af-
fect the parotid lymphoma. BAFF levels decreased only under B-cell depletion associated with high-dose steroids. Tissue 
studies further documented the persistent overexpression of BAFF in the salivary gland pathologic tissue during the dis-
ease course.  
Conclusion: Tissue and systemic overexpression of BAFF may have contributed to resistance to rituximab therapy, in 
MALT lymphoproliferation associated with SS. Thus, alternative treatment strategies should be then considered, possibly 
including BAFF-targeted approaches. 
INTRODUCTION 
  B-cell expansion is a key feature of Sjögren’s syndrome 
(SS), in particular for systemic vasculitis manifestations, and 
for lymphoma development [1]. Accordingly, preliminary 
studies have reported the possible benefits of B-cell deple-
tion with rituximab in the treatment of glandular and extrag-
landular manifestations of primary SS [2]. B-cell activating  
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factor (BAFF), also known as BLyS, plays a critical role in the 
B-cell survival. BAFF is expressed by T and B cells infiltrating 
the salivary glands in SS, as well as by ductal epithelial cells 
[3]. Abnormal BAFF expression has been also demonstrated to 
be involved in different autoimmune diseases and malignant 
lymphoproliferative disorders [4, 5]. Therefore, BAFF overex-
pression in the salivary gland microenvironment may sustain 
the local proliferation of B cells in SS, and may then influence 
in some degree the response to rituximab treatment in this 
disease. Herein, we report clinico-pathologic and biological 
follow-up studies on a SS patient with lymphoma treated un-
successfully with rituximab. These studies highlight the over-
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phoproliferation of mucosa-associated lymphoid tissue 
(MALT)-type lymphoma in SS supporting the hypothesis of a 
role of BAFF for resistance to rituximab in some SS cases 
with MALT lymphoproliferation. 
CASE REPORT 
History 
  We describe the case of a 51-year old woman with pri-
mary SS and mixed cryoglobulinaemia type II with features 
of systemic vasculitis, i.e., purpura, peripheral neuropathy, 
and skin ulcers, which developed a bilateral parotid MALT-
type lymphoma. 
  In 1997 primary SS was diagnosed based on subjective 
and objective dry mouth and dry eye manifestations, positive 
anti-Ro/SSA and anti-La/SSB antibodies and minor salivary 
gland biopsy showing grade 4 on Chisholm and Mason score 
[6]. In July 2002, given the persistence of right parotid en-
largement of recent onset, the patient underwent right parotid 
biopsy diagnosed histologically as non-malignant myoepi-
thelial sialoadenitis (MESA) with lymphoproliferative le-
sions [7], with the presence of a diffuse infiltrate consisting 
of B cells expressing CD20+/CD5-/CD10- phenotype and 
formation of islands of myoepithelial proliferation, in the 
lack of centrocyte-like cells forming broad interconnecting 
strands between lymphoepithelial lesions and broad “halos” 
around the epithelial cell nests. On the same sample, molecu-
lar analysis of variable, diversity and joining (V-D-J) region 
rearrangements of immunoglobulin heavy chain (IgH) genes 
amplified by polymerase chain reaction (PCR) [7] revealed a 
B-cell monoclonal expansion in the pathologic tissue. In 
September 2003 the patient was referred to our Clinic be-
cause of persistent bilateral parotid gland swelling, purpura 
and paresthesias on the lower limbs, with a perimalleolar 
ulcer 2 x 3 cm on the right leg. Hepatitis B and C virus infec-
tions were absent. Electromyography demonstrated a mild 
sensitive axonal polyneuropathy on the lower limbs. Serum 
rheumatoid factor (RF), cryoglobulins and complement frac-
tion C4 levels were 9190 IU/L (normal value < 20 IU/L), 
3256 mg/dl and 7 mg/dl (normal value 10-40 mg/dl), respec-
tively. A second right parotid biopsy showed histological 
features in keeping with the diagnosis of MALT-type B cell 
non Hodgkin’s lymphoma (NHL). B-cell monoclonal expan-
sion in the NHL was detected by repeat V-D-J IgH chain 
rearrangements by PCR. NHL staging was IE, on the basis of 
negative computed tomography thorax and abdomen scan 
and negative bone marrow biopsy. In November 2003 four 
weekly infusions of rituximab 375 mg/m
2 were administered 
without any clinical improvement of the skin ulcer, periph-
eral neuropathy and bilateral parotid swelling. Then, the pa-
tient also failed to show clinical improvement after other 
therapies (oral daily and pulse cyclophosphamide, 9 g in 
total, then azathioprine for three months), while a third re-
peated right parotid biopsy documented the persistence of 
MALT-type lymphoma (July 2004). On February 2005 im-
munosuppressive therapy was discontinued and the patient 
underwent subtotal bilateral parotidectomy. Histopathologic 
analysis showed a B cell MALT-type lymphoma in both 
parotid glands. One month after bilateral parotidectomy, the 
skin ulcer decreased by two thirds in size, and concomitantly 
the RF titre and cryoglobulin level decreased, in the absence 
of any immunosuppressive treatment. Given the persistence 
of skin ulcer and purpura and a biologically active disease 
(RF 3390 IU/L, cryoglobulins 440 mg/dl, C4 6 mg/dl), the 
patient underwent repeated courses of plasma exchange from 
May to June 2005, achieving an almost complete ulcer heal-
ing by August 2005. However, the patient experienced a new 
episode of purpura in the lower limbs and recurrence of the 
perimalleolar skin ulcer one month later (end of September). 
Plasma exchange was started again with the same induction 
schedule used before, but the skin ulcer worsened. In Febru-
ary 2006, right parotid swelling was noticed again. A fourth 
parotid biopsy (February 2006) showed a persistence of 
MALT-type lymphoma, and CT scan confirmed the bilateral 
enlargement of the parotid glands, consistent with local tu-
mor relapse. Eight consecutive rituximab infusions (375 
mg/m
2 weekly), in association with high-dose steroids (1 
mg/kg for 1 month, then slowly reduced to 5 mg of predni-
sone equivalents during the additional 4 months) were ad-
ministered (Fig. 1). RF, cryoglobulins, BAFF levels (meas-
ured by immunosorbent assay, R&D Systems Quantikine 
ELISA kit) (Fig. 1) were assessed monthly up to month +6, 
then at the end of follow-up (month +12), in conjunction 
with peripheral blood CD19-positive B-cell count, immuno-
globulins, C3 and C4 (data not shown). This treatment regi-
men was well tolerated. However, despite a significant sys-
temic effect of rituximab on B-cell biomarkers (reduction in 
RF, cryoglobulin and immunoglobulin levels, and persistent 
depletion in the peripheral blood CD19-positive B cells until 
month +6) the neuropathy did not improve, the skin ulcer 
was reduced only by 25% at month +6 and it worsened at 
month +12, and the parotid enlargement did not decrease, as 
demonstrated by CT scan and ultrasonography. Thus, pro-
longed rituximab therapy plus high-dose steroids did not 
prove effective in the lymphoproliferative and vasculitic 
disease. 
Detection of BAFF Serum Levels Before and After Ri-
tuximab 
  BAFF levels initially decreased but then increased again 
during steroid tapering (at doses < 0.5 mg/kg/day of predni-
sone equivalents), remaining at high levels during the whole 
study period (Fig. 2). 
BAFF Detection in the Pathologic Target Tissues 
  Tissue studies further documented the persistent overex-
pression of BAFF in the salivary gland pathologic tissue 
during the disease course. Immunohistological analysis of 
the parotid biopsy taken in July 2002 (parotid MESA) dem-
onstrated strong local BAFF production. BAFF-positive cells 
were detected within the lymphocytic infiltrate, in particular 
in association with germinal centre-like structures as well as 
in ductal epithelium, and BAFF receptor (BAFF-R) was de-
tected on the majority of the infiltrating lymphocytes and in 
particular in the B lymphocytes populating the germinal cen-
tre mantle zone (Fig. 2A,C). 
  In the lymphomatous parotid biopsy obtained in February 
2005, after rituximab monotherapy, BAFF-positive cells 
were again detected within the dense lymphocytic infiltrate, 
both in the reactive areas and in the areas infiltrated by small 
monocytoid-like malignant B cells. BAFF-R expression was 
widely detected in the B cell area. BAFF and BAFF-R stain-
ing of the ductal epithelium was again detected as well (Fig. 
2B,D). 40    The Open Rheumatology Journal, 2008, Volume 2  Quartuccio et al. 
1,0
10,0
100,0
1000,0
10000,0
100000,0
Baseline
month +1
month +2
month +3
month +4
month +5
month +6
month +12
0
10
20
30
40
50
60
RF U/l
Cryos mg/dl
BLyS pg/ml
MP mg/day
RTX 
 
Fig. (1). Serological changes of rheumatoid factor (RF), cryoglobulins (cryos), BLyS levels and dose changes of daily methylpredniso-
lone (MP) during rituximab (RTX) 650 mg weekly for 8 weeks) infusions and in the subsequent follow-up. RF, cryos and BLyS levels 
are expressed in logarithmic scale on the left side. The scale on the right side of the graphic is related to MP daily dose. 
 
 
Fig. (2).  BAFF and BAFF-R expression in parotid gland (MESA pre-rituximab in the Panel A and C, and MALT NHL post-
rituximab in the Panel B and D) during the follow-up. Microphotograph showing diffuse BAFF (A and B) and BAFF-R (C and D) ex-
pression in the salivary gland of the patient in the parotid biopsies relative to MESA 2002 (A and C) and post-rituximab MALT NHL 2005 
(B and D). BAFF strongly positive cells (brown) were detected in the MESA both inside the infiltrated areas (germinal centres=GC in panel 
A) and in the ducts (data not shown), but intense BAFF expression with the same pattern were detected also in the B-cell MALT NHL de-
spite the treatment with rituximab (panel B). Sequential sections show strong expression of BAFF-R in mantle zone B cells (panel C for the 
MESA), and in the infiltrating lymphocytes surrounding the epithelial structures (panel D for the MALT NHL) (Original magnification 
100x). Rituximab Therapy and Local BAFF Overexpression  The Open Rheumatology Journal, 2008, Volume 2    41 
BAFF Expression in Salivary Gland Culture Studies 
  The salivary gland epithelial cells (SGEC) obtained from 
the parotidectomy surgical specimen in February 2006 were 
maintained in culture (F12 Coon’s modified with 5% FBS, 
and bovine extracts) and characterized by the expression of 
epithelial markers, as previously described [8]. SGECs 
showed significant expression of BAFF both at the mRNA 
(semi-quantitative PCRs, data not shown) and at the protein 
levels (data not shown) [9]. Incubation of SGECs with IFN-
 (10 ng/ml, 48 hours) demonstrated a strong induction of 
BAFF mRNA expression (real-time PCR) and protein re-
lease in the supernatant (Fig. 3) [10]. 
DISCUSSION 
  Low-grade B-cell marginal zone MALT-type lymphoma, 
usually involving the parotid glands, is an important compli-
cation of primary SS [1]. Parotid lymphoma may evolve 
from parotis MESA, which may in turn present with differ-
ent pathologic and molecular patterns of B cell proliferation 
[7]. The possible efficacy of rituximab monotherapy has 
been reported in parotid gland MALT-type lymphoma in 
primary SS, however with contrasting results [2, 11-18], also 
in our early experience [19]. Recently, Seror et al. [18] de-
tected efficacy, however with different degrees of response, 
in 80% of MALT-type lymphoma in SS (Table 1). Thus, non 
responders or partial responders to rituximab are also present 
in SS. The present paper is focused on the possible role of 
local BAFF in influencing the response to rituximab of pa-
rotid lymphoproliferative disorders of SS. 
  This is the first report where salivary glands BAFF ex-
pression has been assessed at different stages of progression 
towards parotid B-cell NHL in SS. BAFF expression within 
the salivary glands was found consistently elevated during 
the disease course, both before and after rituximab treatment. 
BAFF expression was detected in the infiltrating inflamma-
tory cells confirming previously published results [3]. 
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Fig. (3). BAFF expression and secretion modulation by IFN-g stimulation on cultured epithelial cells. (A) BAFF mRNA expression 
was increased more than 80 fold by stimulation with IFN-g 10 ug/ml for 48 hours (Real-time PCR, primers and PCR condition as previously 
described, ref. 10). (B) BAFF concentration in the supernatant increased about 50 fold (from 20110.1 pg/ml to 10811357 pg/ml; measured by 
immunosorbent assay, R&D Systems Quantikine ELISA kit). The experiments were done two times in duplicate. 42    The Open Rheumatology Journal, 2008, Volume 2  Quartuccio et al. 
Moreover, diffuse BAFF expression was detected on the 
ductal epithelium also in parotid MESA and lymphoma SS-
related, and BAFF expression and protein synthesis were 
confirmed by the study of SGECs established from the 
MALT lymphoma of the patient. This further highlights the 
role of the epithelial cells in SS pathogenesis. These data 
extend previous results in epithelial cells from benign minor 
salivary gland lesions in SS [10]. The epithelial salivary cells 
appear then involved not only in the process of antigen pres-
entation, but also in the survival of the infiltrating B cells in 
SS. A possible BAFF autocrine loop may occur also in the 
epithelial compartment in SS, besides the autocrine loop 
hypothesized in proliferating B-cells [9]. 
  After repeated and more prolonged rituximab therapy 
combined with high-dose corticosteroids serum BAFF levels 
somewhat decreased from baseline (but did not normalize) 
when the steroid dose was maintained between 1 mg/kg/day 
and 0.5 mg/kg/day. Then BAFF rapidly increased again 
when the steroid dose was reduced below 0,5 mg/kg/day 
(Fig.  2). Serum RF and cryoglobulins decreased and then 
increased accordingly (Fig. 1). The present report then con-
firms previous data about the partial downregulation of 
BAFF production under medium to high doses of steroids 
[20], which were used with this purpose. However, such a 
partial decrease in BAFF may be clinically ineffective, and 
rituximab may increase BAFF and then in part inhibit such 
steroid-induced BAFF decrease [21]. Overall, as revealed by 
the bilateral parotid swelling, confirmed by CT scan imaging 
and ultrasonography, there was a failure of the combination 
therapy of steroids and rituximab as used in our case. On the 
other hand, a more prolonged high-dose steroid therapy, pos-
sibly keeping a more prolonged BAFF suppression, is not 
advisable in our opinion, due to the possible severe side ef-
fects. Overall, after literature revision and including the pre-
sent case in all the SS patients with MALT-type lymphoma 
Table 1.  Cases With Primary SS and Lymphoma Treated with Rituximab 
 
Author, Years  N. of Pts  Type of Lymphoma/Bone Marrow Involvement  Ann Arbor 
Stage 
Response  Other Concomitantly  
Immunosuppressive Agents 
Somer, 2003  1  Parotid gland MALT-type/no  IE  Yes  No 
Voulgarelis, 2004*  4  1.  Salivary gland MALT-type/yes* 
2.  Nodal marginal zone/no* 
3.  Pulmonary MALT-type/yes* 
4.  Salivary gland MALT-type/yes* 
IV 
IIE 
IV 
IV 
Yes 
Yes 
Yes 
Yes 
1.  CHOP 
2.  CHOP 
3.  CHOP 
4.  CHOP  
Harner, 2004  1  Nodal marginal zone/Pulmonary MALT-type/no  IIE  Yes  No 
Ramos-Casals, 2004  2  1.  Ovarian MALT-type/yes 
2.  Ocular MALT-type/yes 
IV 
IV 
Yes 
Yes 
1.  CHOP 
2.  Local radiotherapy 
Pijpe, 2005  1  Parotid gland MALT-type/no  IE  Yes  No 
Gottenberg, 2005
# 2  1.  Digestive tract MALT-type/no
# 
2.  Salivary gland MALT-type/no
# 
IE 
IE 
Yes 
No 
1.  MP 500 mg x 4, HQ 
2.  No 
Pijpe, 2005  7  1.  Parotid gland MALT-type/no 
2.  Parotid gland MALT-type/no 
3.  Parotid gland MALT-type/no 
4.  Parotid gland MALT-type/no 
5.  Parotid gland MALT-type/no 
6.  Parotid gland MALT-type/no 
7.  Parotid gland MALT-type/no 
IE 
IE 
IE 
IE 
IE 
IE 
IE 
No 
No 
Yes 
Yes 
No 
Yes 
No 
1.  No 
2.  PDN 15 mg/day 
3.  No 
4.  No 
5.  PDN 7.5 mg/day, MTX 
6.  PDN 5 mg/day, AZA 
7.  No 
Voulgarelis, 2006*  6  1.  Nodal marginal zone/no 
2.  DLBCL/no 
3.  Salivary gland MALT-type/yes* 
4.  Nodal marginal zone/no* 
5.  Pulmonary MALT-type/yes* 
6.  Salivary gland MALT-type/yes* 
II 
II 
IV 
IIE 
IV 
IV 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
1.  CHOP 
2.  CHOP 
3.  CHOP 
4.  CHOP 
5.  CHOP 
6.  CHOP 
Seror, 2007
# 5  1.  Salivary gland MALT-type/no
# 
2.  Nodal marginal zone/yes 
3.  Gastric/pulmonary MALT-type/no 
4.  Gastric MALT-type/no
# 
5.  DLBCL/no 
IE 
IV 
IV 
IE 
III 
No 
Yes 
Yes 
Yes 
Yes 
1.  No 
2.  No 
3.  Mini-CHOP 
4.  HQ 
5.  CHOP 
Present report  1  Parotid gland MALT-type/no  IE  No  High-dose steroids 
*There is some patients’ overlapping between the cases reported in Voulgarelis, 2004 and Voulgarelis, 2006. 
#There is some patients’ overlapping between the cases reported in Gottenberg, 2005 and Seror, 2007. 
Abbreviations: pts, patients; MALT, mucosa-associated lymphoid tissue; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; AZA, azathioprine; PDN, prednisone; 
MTX, methotrexate; MP, methylprednisolone; DLBCL, diffuse large B-cell lymphoma; HQ, hydroxychloroquine. Rituximab Therapy and Local BAFF Overexpression  The Open Rheumatology Journal, 2008, Volume 2    43 
treated with rituximab not in the context of chemotherapeutic 
regimen or in association with local radiotherapy, rituximab 
treatment seems to be less effective. When analyzing the 
subset of MALT-type lymphoma involving the salivary 
glands (Table 1), some response is seen in less than half of 
the patients [2, 11-18]. The response to rituximab of SS-
associated lymphoma may be also different with regard to 
the different histotype of lymphoma and to the tissue in-
volved [22]. Rituximab alone may fail to deplete B-cells in 
the target tissue, due to the resistance of peculiar B-cell sub-
types, e.g., MZ B cells, and to microenvironment local fac-
tors, as recently well described in a murine model [23]. In 
these mice, tissue BAFF expression reduced the effect of B-
cell depletion, while concomitant BAFF inhibition allowed 
to reach much higher degrees of B-cell depletion [23]. 
  In conclusion, clinico-pathologic and biological follow-
up studies allowed to highlight overexpression of BAFF 
from pre-malignant to malignant B-cell lymphoproliferation 
of MALT in SS. Lymphoproliferation was resistant to ri-
tuximab therapy, even when associated with high dose corti-
costeroids. Targeting directly the B-cell compartment may 
be then promising for some SS clinical features, but other 
novel therapeutic strategies, targeting indirectly the B cells, 
e.g., anti-BAFF agents, should be explored, with possible 
drug combination [24]. 
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